SPIL” (SciClone International Pharmaceuticals Limited) Zadaxin in China Zadaxin was launched in China in 1996. The brand is well established today with $54 mln in sales last year and guidance for $60-70 million this year. The company has 175 medical representatives on the ground in China today and boasts relationships with over 500 hospitals in China. Zadaxin is used mainly by liver specialists but its use is spreading with oncology specialists and intensive care physicians as a broad immuno-stimulant. Geographaphically the company is now expanding into China’s 2nd and 3rd tier cities. Going forward, SciClone hopes to leverage the China network by acquiring additional products